Attention Deficit Hyperactivity Disorder
📧 Sign up to get email alerts when something new happens for Attention Deficit Hyperactivity Disorder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-08-17Clinical Trial Update: Improving Attention Deficit Hyperactivity Disorder Treatment Adherence and Outcome in Primary Care Settings [NA]
This update notes the completion of a clinical trial aimed at improving adherence to ADHD treatment and outcomes in primary care settings.
-
FDA approval · 2015-08-14FDA Approved: METHYLPHENIDATE TRANSDERMAL SYSTEM — Supplemental Application (PADAGIS US LLC)
FDA approved a supplemental application for the Methylphenidate Transdermal System by PADAGIS US LLC.
-
FDA approval · 2015-08-14FDA Approved: METHYLPHENIDATE HYDROCHLORIDE — Original Application (Lupin Pharmaceuticals,Inc.)
FDA approved Lupin Pharmaceuticals' methylphenidate hydrochloride generic under an Original Application (ANDA 204602); this provides a gener…
-
FDA approval · 2015-08-13FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for dexmethylphenidate hydrochloride from Teva Pharmaceuticals USA, Inc., signaling an addition …
-
FDA approval · 2015-08-13FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA approved a supplemental application for a generic dexmethylphenidate hydrochloride product manufactured by Teva Pharmaceuticals USA,…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-08-10Clinical Trial Update: Effectiveness Study of a Behavioral Teacher Program Targeting ADHD Symptoms [NA]
This document reports the completed results of a study evaluating the effectiveness of a behavioral teacher program targeting ADHD symptoms.
-
CLINICAL_TRIALS trial_result · 2015-08-06Clinical Trial Update: Lisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) [Phase 4]
Phase 4 safety study updating on long-term lisdexamfetamine dimesylate use in children and adolescents with ADHD; results posted in 2015.
-
CLINICAL_TRIALS trial_result · 2015-08-05Clinical Trial Update: Medication Integration in Treatment of Comorbid Adolescent Substance Users/Attention Deficit Hyperactivity Disorder [Phase 1]
A Phase 1 trial evaluating medication integration for adolescents with co-occurring ADHD and substance use disorders has completed.
-
FDA approval · 2015-08-05FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Original Application (Amneal Pharmaceuticals of New York LLC)
FDA approved the original ANDA for dexmethylphenidate hydrochloride from Amneal Pharmaceuticals of New York LLC, a generic formulation for A…
-
CLINICAL_TRIALS trial_result · 2015-08-04Clinical Trial Update: Family-Based Protocol for Medication Integration in Treatment of Comorbid ASU/ADHD in Routine Care [Phase 1]
Phase 1 clinical trial update noting completion of testing a family-based protocol to integrate medications for adolescents with comorbid su…
-
CLINICAL_TRIALS trial_result · 2015-08-04Clinical Trial Update: Implementation of Climb Up Program for Children With Attention Deficit Hyperactivity Disorder (ADHD) and Dyslexia in a School in India [Phase 1, Phase 2]
This clinical trial update notes the completion of the Climb Up program implementation for children with ADHD and dyslexia in an Indian scho…
-
EMA approval · 2015-07-24EMA recommends approval of treatment for attention deficit hyperactivity disorder
EMA recommends approval of a new treatment for attention deficit hyperactivity disorder, indicating positive assessment of its benefit-risk …
-
FDA approval · 2015-07-13FDA Approved: QUILLIVANT XR — Supplemental Application (NextWave Pharmaceuticals, Inc)
The FDA approved a supplemental application for QUILLIVANT XR (methylphenidate hydrochloride) from NextWave Pharmaceuticals, Inc.
-
CLINICAL_TRIALS trial_result · 2015-07-09Clinical Trial Update: Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy [Phase 3]
Phase 3 trial update reporting safety and tolerability of the methylphenidate transdermal system (MTS) in children aged 6-12 with ADHD previ…
-
CLINICAL_TRIALS trial_result · 2015-07-09Clinical Trial Update: Efficacy, Safety and Tolerability of SPD485 in Children Aged 6-12 Diagnosed With ADHD [Phase 2]
Phase 2 trial update assessing SPD485 in children aged 6-12 with attention deficit hyperactivity disorder, focusing on efficacy, safety, and…
-
CLINICAL_TRIALS trial_result · 2015-07-09Clinical Trial Update: PRC-063 in an ADULT Workplace Environment [Phase 3]
Phase 3 trial of PRC-063 for attention-deficit/hyperactivity disorder in adults completed, sponsored by Rhodes Pharmaceuticals, L.P., evalua…
-
CLINICAL_TRIALS trial_result · 2015-07-08Clinical Trial Update: PRC-063 in Adolescent ADHD [Phase 3]
Phase 3 clinical trial PRC-063 in adolescents with ADHD has completed.
-
CLINICAL_TRIALS trial_result · 2015-07-08Clinical Trial Update: Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD [Phase 3]
The document summarizes long-term safety data from a Phase 3 study of PRC-063 in adolescents and adults with ADHD. The trial has completed.
-
CLINICAL_TRIALS trial_result · 2015-07-08Clinical Trial Update: Atomoxetine for Attention Deficit Hyperactivity Disorder in Adolescents With Substance Use Disorder [NA]
This clinical trial update reports completion of a study evaluating atomoxetine for attention-deficit/hyperactivity disorder in adolescents …
-
FDA approval · 2015-06-30FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE — Supplemental Application (Par Health USA, LLC)
FDA approved a supplemental application for a generic dexmethylphenidate hydrochloride extended-release product by Par Health USA, LLC.
-
CLINICAL_TRIALS research · 2015-06-26Clinical Trial Update: EAA/Therapy for Treating Children With ADHD [NA]
An update on a clinical trial of EAA/Therapy for treating children with Attention Deficit Hyperactivity Disorder; sponsor is Samsung Medical…
-
CLINICAL_TRIALS trial_result · 2015-06-25Clinical Trial Update: Classroom Study to Assess Efficacy and Safety of MTS in Pediatric Patients Aged 6-12 With ADHD [Phase 2]
A Phase 2 classroom-based study evaluating the efficacy and safety of MTS in children aged 6-12 with ADHD has completed. The trial was spons…
-
CLINICAL_TRIALS trial_result · 2015-06-25Clinical Trial Update: Safety and Efficacy of MTS Versus Concerta in Pediatric Patients (Aged 6-12 Years) With ADHD [Phase 3]
Phase 3 trial comparing Methylphenidate Transdermal System (MTS) to Concerta in children aged 6-12 with ADHD has completed, assessing safety…
-
CLINICAL_TRIALS trial_result · 2015-06-24Clinical Trial Update: Omega-3 Fatty Acids Supplementation in ADHD [Phase 3]
Phase 3 trial evaluating omega-3 fatty acid supplementation for attention-deficit/hyperactivity disorder has been terminated. The update pro…
-
FDA approval · 2015-06-15FDA Approved: METHYLPHENIDATE HYDROCHLORIDE CD — Supplemental Application (Lannett Company, Inc.)
FDA approved a supplemental application for methylphenidate hydrochloride CD from Lannett Company, Inc.